Hubert Köster
YOU?
Author Swipe
View article: Repurposing Nitazoxanide for Potential Treatment of Rare Disease Lymphangioleiomyomatosis
Repurposing Nitazoxanide for Potential Treatment of Rare Disease Lymphangioleiomyomatosis Open
Lymphangioleiomyomatosis (LAM) is a rare genetic lung disease. Unfortunately, treatment with the mTORC1 inhibitor Rapamycin only slows disease progression, and incomplete responses are common. Thus, there remains an urgent need to identify…
View article: Solid phase sequencing of biopolymers
Solid phase sequencing of biopolymers Open
This invention relates to methods for detecting and sequencing target nucleic acid sequences, to mass modified nucleic acid probes and arrays of probes useful in these methods, and to kits and systems which contain these probes. Useful met…
View article: Solid phase sequencing of double-stranded nucleic acids
Solid phase sequencing of double-stranded nucleic acids Open
This invention relates to methods for detecting and sequencing of target double-stranded nucleic acid sequences, to nucleic acid probes and arrays of probes useful in these methods, and to kits and systems which contain these probes. Usefu…
View article: A novel approach to detect resistance mechanisms reveals FGR as a factor mediating HDAC inhibitor SAHA resistance in B‐cell lymphoma
A novel approach to detect resistance mechanisms reveals FGR as a factor mediating HDAC inhibitor SAHA resistance in B‐cell lymphoma Open
Histone deacetylase (HDAC) inhibitors such as suberoylanilide hydroxamic acid (SAHA) are not commonly used in clinical practice for treatment of B‐cell lymphomas, although a subset of patients with refractory or relapsed B‐cell lymphoma ac…